AIM: This study evaluated the curative potential of Crinum giganteum in the treatment of schizophrenia using an NMDA-receptor antagonist-induced schizophrenic Wistar rat model. METHODS: Twenty-five adult Wistar rats of both sexes of average weights 180 g were divided into two groups: control and schizophrenic rat models. The controls received 0.1 ml of 0. 9% saline, while schizophrenia was induced in models using 25 mg/kg of ketamine hydrochloride (i.p.) for 7 days. On the 8 day models were divided into group’s k1, k2, k3 and k4 of 5 rats each. K1 and the controls were sacrificed then, groups k2 and k3 were treated with 5 mg/kg and 10 mg/kg aqueous leaf extract of Crinum giganteum while, k4 (standard) received 25 mg/kg of chlorpromazine o...
Background: It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate re...
Background: Dysfunction of dopaminergic, GABAergic and glutamatergic function underlies many core sy...
Introduction: Negative symptoms associated with cognitive impairment as a core symptom of schizophre...
Impairments of N-methyl-D-aspartate receptor (NMDAR) activity have been implicated in several neurop...
Acute administration of NMDA receptor antagonists such as PCP and ketamine are accepted models of sc...
Background: Crinum zeylanicum is widely used in the ethno-therapeutic management of folk management ...
YesCognitive deficits in schizophrenia remain an unmet clinical need. Improved understanding of the ...
Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia...
The hypo-NMDA receptor function hypothesis for schizophrenia is a model that is currently receiving ...
Newer antipsychotics with improved efficacy and fewer side effects are necessary in view of the curr...
Patients with schizophrenia, and rodent models of the disease, both exhibit suppressed neurogenesis,...
Altered glutamate signaling contributes to a myriad of neural disorders, including schizophrenia. Wh...
A large number of cellular level abnormalities have been identified in the hippocampus of schizophre...
Abstract\ud \ud Background\ud Better treatments for sc...
© 2020, The Author(s). Despite several compounds entering clinical trials for the negative and cogni...
Background: It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate re...
Background: Dysfunction of dopaminergic, GABAergic and glutamatergic function underlies many core sy...
Introduction: Negative symptoms associated with cognitive impairment as a core symptom of schizophre...
Impairments of N-methyl-D-aspartate receptor (NMDAR) activity have been implicated in several neurop...
Acute administration of NMDA receptor antagonists such as PCP and ketamine are accepted models of sc...
Background: Crinum zeylanicum is widely used in the ethno-therapeutic management of folk management ...
YesCognitive deficits in schizophrenia remain an unmet clinical need. Improved understanding of the ...
Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia...
The hypo-NMDA receptor function hypothesis for schizophrenia is a model that is currently receiving ...
Newer antipsychotics with improved efficacy and fewer side effects are necessary in view of the curr...
Patients with schizophrenia, and rodent models of the disease, both exhibit suppressed neurogenesis,...
Altered glutamate signaling contributes to a myriad of neural disorders, including schizophrenia. Wh...
A large number of cellular level abnormalities have been identified in the hippocampus of schizophre...
Abstract\ud \ud Background\ud Better treatments for sc...
© 2020, The Author(s). Despite several compounds entering clinical trials for the negative and cogni...
Background: It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate re...
Background: Dysfunction of dopaminergic, GABAergic and glutamatergic function underlies many core sy...
Introduction: Negative symptoms associated with cognitive impairment as a core symptom of schizophre...